Jove
Visualize
联系我们

相关概念视频

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
  1. 首页
  3. 透瘤的cd103+cd8+hnrnpa2b1+组织t细胞表明清细胞癌患者的预后不佳
  1. 首页
  3. 透瘤的cd103+cd8+hnrnpa2b1+组织t细胞表明清细胞癌患者的预后不佳

相关实验视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

透瘤的CD103+CD8+hnRNPA2B1+组织T细胞表明清细胞癌患者的预后不佳

Yingting Liu1,2,3, Jiajin Ma1,2,3, Bin Xu1,2,3

  • 1Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, People's Republic of China.

Journal of leukocyte biology
|August 25, 2025

在PubMed 上查看摘要

概括
此摘要是机器生成的。

瘤透的CD103+CD8+hnRNPA2B1+T细胞与清细胞癌 (ccRCC) 的较差结果有关. 更高的透预测不良的预后,可能表明对PD-1免疫疗法的反应.

关键词:
CD103+CD8+在组织中存在的T细胞清细胞细胞癌一个小时的时间多色免疫组织化学染色预后情况

更多相关视频

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K
Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment
06:05

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

8.1K

相关实验视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K
Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment
06:05

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

8.1K

科学领域:

  • 免疫学
  • 癌症学
  • 翻译医学

背景情况:

  • 瘤异质性和复杂的免疫微环境阻碍了使用主导生物标志物的免疫治疗候选者识别.
  • CD8+ T 细胞,特别是 CD103+ CD8+ 等组织寄存子集,在许多癌症中与更好的结果有关,但它们在癌中的作用尚未得到充分研究.

研究的目的:

  • 研究瘤透的CD103+CD8+T细胞及其子集,特别是CD103+CD8+hnRNPA2B1+在清细胞细胞癌 (ccRCC) 的预后意义.
  • 评估这些T细胞子集与患者的预后和PD-1免疫疗法的反应之间的关联.

主要方法:

  • 用多重免疫光染色来评估ccRCC组织中的CD103+CD8+T细胞子集.
  • 进行T细胞透水平与患者临床病理特征和预后之间的相关性分析.
  • 对接受PD- 1治疗的ccRCC患者的单细胞转录组数据进行了分析,以比较响应者与不响应者的hnRNPA2B1表达.

主要成果:

  • 与正常邻近组织相比,ccRCC组织中CD103+CD8+T细胞,CD103+CD8+hnRNPA2B1+T细胞和CD103+CD8+Bhlhe40+T细胞的透率显著更高 (P < 0. 01).
  • 这些子组的透率较高与总生存率较低相关,并作为ccRCC患者的独立预后因素 (分别为P=0. 0144和P=0. 013).
  • 响应PD- 1治疗的瘤透性CD8+ T细胞表现出较高的hnRNPA2B1表达.

结论:

  • 瘤透的CD103+CD8+hnRNPA2B1+组织T细胞代表了ccRCC的不良预后因素.
  • 这些T细胞子集可以作为预测性生物标志物来预测患者对基于PD-1的免疫治疗的反应.
  • 对这些特异性T细胞群的进一步研究可以完善ccRCC的免疫治疗策略.